{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 42,
        "end": 69
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 102,
        "end": 109
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 72,
        "end": 77
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 223,
        "end": 245
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 248,
        "end": 251
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 268,
        "end": 292
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 295,
        "end": 298
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 90,
        "end": 99
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 31,
        "end": 169
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "15020609_2",
  "text": "PURPOSE : To determine whether adding the multidrug resistance gene-1 ( MDR-1 ) modulator valspodar ( PSC 833 ; Novartis Pharmaceuticals , Hanover , NJ ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia ( AML ) and high-risk myelodysplastic syndrome ( MDS ) ."
}
